FDA Guidance Allows Limited Foreign Data To Approve Devices With Postmarket Caveat

As FDA puts more emphasis on postmarket data collection in its PMA approval process, the agency has released a final guidance on balancing premarket and postmarket studies.

More from Archive

More from Medtech Insight